Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | CES1 | P23141 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7206009 | 0.81 | CES2 (0.47) | CES2CES1 | |
| SCHEMBL28679402 | 0.76 | PKM (0.33) | APLNRPKM | |
| SCHEMBL30848143 | 0.75 | APLNR (0.43) | APLNRCES2CES1PKM | |
| SCHEMBL2478679 | 0.75 | APLNR (0.43) | APLNRCES2CES1PKM | |
| SCHEMBL6858040 | 0.75 | APLNR (0.43) | APLNRCES2CES1PKM | |
| SCHEMBL3708094 | 0.75 | APLNR (0.43) | APLNRCES2CES1PKM | |
| SCHEMBL29413826 | 0.72 | CFTR (0.37) | — | |
| SCHEMBL1345953 | 0.72 | ADRA2C (0.46) | APLNRPKM | |
| SCHEMBL1343758 | 0.72 | APLNR (0.36) | APLNRCES2CES1PKM | |
| SCHEMBL11867787 | 0.72 | HDAC3 (0.36) | APLNRCES2CES1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12275742-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2024-10-24 | — | — | US | disclosed |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230107663-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230076627-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20230076627-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2023-03-09 | — | — | US | disclosed |
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220340586-A9 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220098212-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2021226269-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226208-A2 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098212-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | APLNR 4204/4885CES2 212/4885CES1 804/4885 |
| US-12275742-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, PAICS | APLNR 4276/4885CES2 205/4885CES1 769/4885 |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, PAICS | APLNR 4276/4885CES2 205/4885CES1 769/4885 |
| US-20230076627-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | CYP2C8, ABCB1, PAICS | APLNR 4276/4885CES2 205/4885CES1 769/4885 |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | CYP2C8, ABCB1, PAICS | APLNR 4276/4885CES2 205/4885CES1 769/4885 |
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | APLNR 4411/4885CES2 283/4885CES1 1288/4885 |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | APLNR 4597/4885CES2 512/4885CES1 940/4885 |
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | APLNR 4597/4885CES2 512/4885CES1 940/4885 |
| US-20230107663-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | APLNR 4411/4885CES2 283/4885CES1 1288/4885 |
| US-20220340586-A9 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | APLNR 4204/4885CES2 212/4885CES1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.